ZYBERNO
Stock Report
Updated Sep 1, 2026

CADRENAL THERAPEUTICS, INC. (CVKD)

Healthcare • NASDAQ

$1.48

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
CADRENAL THERAPEUTICS, INC. (CVKD) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-406.4%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-509.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

CADRENAL THERAPEUTICS, INC. (CVKD) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, CVKD generated -$12.61M in Owner Earnings. Capital was deployed as follows: $5.10K invested in capital expenditures. Reinvestment rate: 0.0%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.48
Market Cap:$4.31M

Valuation Multiples (2)

P/B Ratio:1.05x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$1.94M

Price Action & Momentum (3)

Momentum Percentile:3 / 100
% of 52-Week High:10.1%
B. Profitability Assessment

Return Metrics (5)

ROA:-273.8%
Reinvestment Rate:0.0%
Fundamental Growth Rate (g):-0.1%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$259.89
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:51.7%
Latest Earnings Filed:2026-08-13
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:3.73x
Quick Ratio:3.73x
Cash Ratio:1.60x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:4,086,866.00
Cash And Cash Equivalents:2,388,135.00
Long Term Debt:$2.23K
Net Debt:-$2.38M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$11.65M

Bottom Line Performance (3)

-$11.54M
Income Before Tax:-$13.24M
Ebitda Ttm:-11,651,673.00

Operating Expenses (5)

Operating Expenses:11,653,688.00
R And D Expense:2,831,447.00
Sga Expense:8,820,226.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$5.59M
Current Assets:$5.58M
Ppe Net:2,675.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:1,497,257.00
Current Liabilities:1,497,257.00
Long Term Debt:$2.23K
Short Term Debt:$9.38K

Equity & Capital (3)

Equity:$4.09M
Retained Earnings:-$44.78M
Common Stock:75,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:871,913.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:672,102.00
C. Cash Flow Analysis

Operating Activities (2)

-$10.96M-$10.96M

Investment Activities (2)

Investing Cash Flow:$0.00
Capital Expenditures Ttm:5,104.00

Financing Activities (3)

Financing Cash Flow:$1.30M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:-63,970.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:2,015.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-4.86
-$4.86
Earnings Per Share Ttm:-$3.96

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$4.33

Book Value & Capital (2)

Book Value Per Share:$1.40
Cash Per Share:0.82

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$12.61M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):-0.1%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-16.5%
C. Company Profile & Context

Corporate Information (6)

Symbol:CVKD
Company Name:CADRENAL THERAPEUTICS, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:2.91M
Shares Outstanding Basic:2.91M
Shares Outstanding Diluted:2.91M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 14:45:21 UTC
Data Timestamp:2026-08-21T13:19:18.438083
Scroll to Top